Pharmaceuticals News

SYDNEY, AUSTRALIA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies...

GeneCentric to give oral presentation on Oct. 23 at ASHG 2026 highlighting fragmentomics-based ExpressCT™ liquid biopsy technology

NASHVILLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced the appointment of Donnie Purto as Senior Vice President of Sales to lead the...

Rhea’s Factory’s AI-designed enzymatic PET recycling to be validated by DOE and Berkeley Lab at Niagara Bottling’s rPET facility in Vernon, California.

GACP Certification from Perry Johnson Supports Pathway to International Markets This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated...

New preclinical data demonstrates PS-003 restores the key collagen protein missing in X-linked Alport Syndrome (XLAS) and is presented alongside findings from one of the largest genetic studies of...

FLINTLOCK Phase 2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in adults aged 18-65 years with Long COVID or...

Entrada Therapeutics announces that an independent DMC recommends initiation of Cohort 3 at the top dose of 18 mg/kg in the ELEVATE-44-201 study.

Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer

FDA’s Rare Disease Evidence Principles (RDEP) process aims to provide greater speed and predictability in the review of therapies for rare diseases with significant unmet medical need Acceptance...